# Neovacs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neovacs

- Industry: Biotechnology
- Headquarters: Suresnes, France
- Website: www.neovacs.fr
- Total disclosed funding: $18M
- Latest round: Series A (Jul 18, 2007)
- Investors on record: 3

## About

Neovacs SA, based in France, is a biotechnology company dedicated to developing immunotherapeutic solutions utilizing its proprietary Kinoïde technology platform to treat autoimmune diseases and allergies.Neovacs SA specializes in immunotherapy aimed at treating conditions such as lupus and allergies. The company is headquartered in Suresnes, France. Neovacs has successfully completed 14 funding deals, with its latest funding round being a PIPE of EUR 8.000 mn, bringing the total amount raised to EUR 8.000 mn. The company has seen changes in its business operations, particularly in refining its therapeutic offerings in response to market needs.Neovacs focuses on innovative therapeutic solutions through its Kinoïde technology platform. The main products include Kinoide® IFNa for lupus treatment and Kinoide® IL-4/IL-13/IgE for allergies. These products leverage the body's immune response to diminish harmful cytokine overproduction. Neovacs collaborates with various pharmaceutical and healthcare partners in Europe and North America to enhance its product portfolio.In the most recent fiscal year 2023, Neovacs reported a revenue of EUR 582,641.20 and an EBITDA of EUR -7,299,279.50. The company's revenue model comprises product sales and strategic partnerships with pharmaceutical companies, often engaging in collaboration agreements for licensing fees and research funding.Neovacs plans to expand its product lineup and aims to introduce new therapeutic candidates targeting autoimmune diseases by mid-2024. The company is also targeting expansion into additional markets in Europe and North America. The recent PIPE funding of EUR 8.000 mn will support these initiatives, allowing Neovacs to bolster its R&D efforts and enhance its market presence.

## Funding rounds

- Series A, Jul 18, 2007, $18M — Truffle Capital, Novartis Venture Fund, APICAP

## Investors

- Truffle Capital (https://capitalatlas.ai/funds/truffle-capital) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- APICAP (https://capitalatlas.ai/funds/apicap) — Series A